Renal Pelvis and Ureter Urothelial Carcinoma
Associated Genetic Biomarkers
NCI Definition: A transitional cell carcinoma that arises from the renal pelvis and ureter. 
Renal pelvis and ureter urothelial carcinomas most frequently harbor alterations in TP53, KMT2D, FGFR3, KDM6A, and ARID1A .
TP53 Mutation, FGFR3 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and KMT2D Mutation are the most common alterations in renal pelvis and ureter urothelial carcinoma .
There are 6 clinical trials for renal pelvis and ureter urothelial carcinoma, of which 6 are open and 0 are completed or closed. Of the trials that contain renal pelvis and ureter urothelial carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open).
PD-L1 is the most frequent gene inclusion criterion for renal pelvis and ureter urothelial carcinoma clinical trials .
Durvalumab, cisplatin, and gemcitabine are the most common interventions in renal pelvis and ureter urothelial carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.